Summary: For postmenopausal women with ER-positive, metastatic disease, tamoxifen, an aromatase inhibitor or fulvestrant are essentially equivalent choices.
Summary: For postmenopausal women with ER-positive, metastatic disease, tamoxifen, an aromatase inhibitor or fulvestrant are essentially equivalent choices.